need to offer maximum effort surgery (MES) with the aim of complete cytoreduction (R0 resection), to improve survival. The objective of this study is to analyse the implementation of a paradigm shift in the surgical management of women with AOC at the University Hospitals of Leicester NHS Trust (UHL) in 2015, until 2020, compared to 2011–2014.

Methodology Retrospective cohort study of women with AOC who underwent cytoreductive surgery (CRS). The two groups were: 153 women from January 2011 to December 2014 (group 1), 136 women from January 2015 to January 2020 (group 2).

Results In group 1, the 1 year, 3 years and 5 years overall survival rates (OS) were 90.4%, 33.7% and 19.3%, compared to 90.2%, 55.4% and 29.7%, respectively, in group 2 (p=0.012). Significantly more women had CRS in group 2: 45 – Primary debulking surgery (PDS) and 57 – interval debulking surgery (IDS) vs. 17 – PDS & 67 – IDS in group 1 (P<0.001). Surgical complexity score (modified Aletti score) was higher in group 2 compared to group 1 (ps≤0.001). No significant difference was noted in the postoperative complications, in group 2, in women who underwent PDS vs. IDS, yet PDS was associated with higher OS.

Conclusion The transition from standard surgery to maximal effort surgery in AOC patients (a paradigm shift in surgical approach) had a positive impact on OS and PFS rates in our institution. Our data highlights the importance of a dedicated team to implement this change in cancer centres treating AOC. In women who had maximum effort cytoreductive surgery from 2015 onwards, PDS was associated with higher survival rates and comparable post-operative complications than IDS although the surgical complexity was higher in the PDS group.

Abstract 2022-RA-686-ESGO Figure 1 IDS and PDS 1 between 2014-2011, IDS 2 and PDS 2 between 2020-2015

2022-RA-687-ESGO ARTISTRY-7: PHASE 3, MULTICENTER STUDY OF NEMVALEUKIN ALFA PLUS PEBrolizumab VERSUS CHEMOTHERAPY IN PATIENTS WITH PLATINUM-RESISTANT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER (GOG-3063; ENGOT- OV68)

1Thomas J Herzog, 2Kathleen Moore, 3Panagiota A Konstantinopolous, 4Lucy Gilbert, 5John L Hays, 6Bradley J Monk, 7David M O’Malley, 8Joyce N Bariin, 9Julie R Graham, 10Monali Desai, 11Yan Wang, 12Yangchun Du, 13Rita Dalal, 14Robert L Coleman, 15Iland Selhouli, 16Panvel, newton, MA; 17Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK; 18Dana-Farber Cancer Institute, Boston, MA; 19McGill University Health Centre, Woman’s Health Research Unit, Montreal, QC, Canada; 20Wexner Medical Center and James Cancer Hospital, Ohio State University, Columbus, OH; 21Arizona Oncology, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ; 22James Gynecologic Oncology Mill Run, Ohio State University, Hillard, OH; 23Women’s Cancer Care Associates, Albany, NY; 24Akeremes, Inc, Walhamp, MA; 25Texas Oncology, The Woodlands, TX; 26Charité Universitätsmedizin Berlin Charité Campus Virchow-Klinikum, Berlin, Germany

10.1136/ijgc-2022-ESGO.546

Introduction/Background ARTISTRY-7 will evaluate the novel engineered cytokine nemvaleukin alfa (nemvaleukin, ALKS 4230) in patients with gynecological cancers. Epithelial ovarian cancer (EOC) is the 7th most common cause of cancer mortality in women, and many patients become resistant/refractory to frontline platinum-based chemotherapy. Nemvaleukin was designed to selectively bind to the intermediate-affinity interleukin-2 receptor, preferentially activating antitumour CD8+ T and NK cells with minimal regulatory T cell expansion. This selectivity may provide enhanced tumour killing and improved safety/tolerability versus high-dose interleukin-2. In ARTISTRY-1, responses were observed with nemvaleukin+pembrolizumab in 4 patients with platinum-resistant ovarian cancer: 2 complete responses (1 in a patient with 5 prior lines of therapy), and 2 partial responses.

Methodology ARTISTRY-7 (NCT05092360) is an ongoing, currently enrolling phase 3, multicentre, randomised study of nemvaleukin and/or pembrolizumab versus chemotherapy. Eligible patients are women (≥18 years) with histologically confirmed EOC (high-grade serous, endometrioid, clear cell), fallopian tube cancer, or primary peritoneal cancer. Patients must have had ≥1 prior line of systemic therapy (platinum-sensitive setting), ≤3 prior lines (platinum-resistant setting), and prior bevacizumab, with radiographic progression on most recent therapy. Patients with primary platinum-refractory disease (progression on first-line platinum therapy) or primary platinum resistance (progression <3 months after first-line platinum therapy completion) are excluded. Approximately 376 patients are being randomised (3:1:1:3) to receive nemvaleukin 6 µg/kg intravenously (days 1–5) + pembrolizumab 200 mg intravenously (day 1) of each 21-day cycle, pembrolizumab or nemvaleukin monotherapy, or chemotherapy, and stratified by PD-L1 status, histologic subtype, and chemotherapy (paclitaxel vs others). Patients will continue treatment until disease progression or

Int J Gynecol Cancer 2022;32(Suppl 2):A1–A504

A255
intolerable toxicity (maximum 35 pembrolizumab cycles; nivmaleukin can be continued). Primary endpoint: investigator-assessed progression-free survival (RECIST v1.1) in the nivmaleukin+pembrolizumab versus chemotherapy arms. Secondary/exploratory endpoints include overall survival, other anti-tumour measures, safety, health-related quality of life, and pharmacokinetic/pharmacodynamic effects.

**Results** not applicable

**Conclusion** not applicable

---

**2022-RA-688-ESGO**

**SURVIVAL OUTCOMES OF ADVANCED OVARIAN CANCER PATIENTS UNDERGOING MAXIMAL EFFORT CYTOREDUCTION**


10.1136/ijgc-2022-ESGO.547

**Introduction/Background** Surgery remains one of the main treatment modalities for the treatment of ovarian cancer. Patients with advanced stage disease will likely undergo neoadjuvant chemotherapy as the majority of surgeons is not familiarized with maximal effort cytoreduction. The purpose of the present study is to evaluate morbidity and mortality outcomes of ovarian cancer patients undergoing procedures with and intermediate and high complexity score.

**Methodology** We performed a retrospective chart review of patients undergoing intermediate and high complexity procedures (according to the Mayo Clinic classification system) between 2008 and 2020. We assessed morbidity and survival outcomes in order to evaluate which subgroups benefited the most from maximal effort cytoreduction.

**Results** Overall 107 patients were included with a median duration of follow-up of 45 months (24–156). The median surgical complexity score was 7 (4–15). The progression free and overall survival rates of the entire cohort were 28 (22 – 34) and 47 (37–57) months respectively. Sixteen patients experienced a grade IIIB Clavien-Dindo complication. Median high dependency unit stay was 3 days (1–15). Five patients required hospitalization in the intensive care unit. Patients undergoing primary debulking had a clear overall survival benefit compared to patients that had interval debulking surgery (54 months (40–67) vs 35 months (24–46)). Kaplan Meier curves revealed that the difference became evident among patients that survived for at least 50 months. Recurrence free survival was not influenced by this parameter. A progressive decrease in overall survival rates was observed with advancing stage. Complexity of the procedure (intermediate vs high) did not affect survival rates of patients.

**Conclusion** Maximal effort cytoreduction is feasible and is accompanied by acceptable morbidity and mortality rates. Primary debulking should be considered in appropriately selected patients as this considerably increases overall survival rates of patients.

---

**2022-RA-703-ESGO**

**PRIMARY AND INTERVAL DEBULKING SURGERY IN ADVANCED OVARIAN CANCER: REAL-WORLD CLINICAL OUTCOMES OF PATIENTS IN 1ST LINE SETTING, ANALYSIS FROM THE FRENCH NATIONAL ESME-UNICANCER DATABASE**

Hélène Costaz, Amal Boussenc, Quentin Dominique Thomas, Isabelle Ray-Coquard, Christophe Pomel, Laurence Gladieff, Frédéric Marchal Marchal, Enora Las, Roman Rozier, Renaud Sabatier, Anne Floquet, Thibault de la Motte Rouge, Patricia Pautier, Eric Leblanc, Emmanuel Barranger, Thierry Petit, Frédéric Fiten, Pierre-Emmanuel Colombo, Anne-Laure Martin Martin, Jean-Marc Classe. 1Department of Surgical Oncology, Centre Georges François Leclerc, Dijon, France; 2Department of Biometry, Institut du Cancer de Montpellier, Montpellier, France; 3Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France; 4Department of Medical Oncology, Centre de Cancérologie de Lorraine, Vandoeuvre-Les-Nancy, France; 5Department of Medical Oncology, Institut Curie, Paris, France; 6Department of Surgical Oncology, Centre François Baclesse, Caen, France; 7Department of Medical Oncology, Institut Pitié-Salpêtrière, Paris, France; 8Department of Medical Oncology, Institut Bergonie, Bordeaux, France; 9Department of Medical Oncology, Centre Eugène Marquis, Rennes, France; 10Department of Medical Oncology, Gustave Roussy, Villejuif, France; 11Department of Surgery, Centre Oscar Lambret, Lille, France; 12Department of Surgery, Centre Antoine Lacassagne, Nice, France; 13Department of Medical Oncology, Institut de Cancérologie, Strasbourg, France; 14Department of Medical Oncology, University Hospital of Nîmes, University of Montpellier, UMR UA11 INSMR, DESP Institut Desbret d’Epidémiologie et de Santé Publique, Montpellier, France; 15Department of Surgery, Institut du Cancer de Montpellier, Montpellier University, Montpellier, France; 16Unicancer, Health Data and Partnership Department, Paris, France; 17Department of Surgical Oncology, Institut de Cancérologie de l’Ouest Centre René Gauducheau, Saint Herblain, France

10.1136/ijgc-2022-ESGO.548

**Introduction/Background** Primary cytoreductive surgery is the standard of care for advanced ovarian cancer. This work would like to explore the prognostic according the surgical management in advanced ovarian cancer of a real-world multicentre cohort.

**Methodology** A non-interventional, retrospective study in patients selected from the Epidemio-Strategy and Medical Economics (ESME) Ovarian Cancer (OC) Data Platform of Unicancer, a multicentre real-life database using a supervised, retrospective data collection process was conducted.

Patients treated with surgery for advanced ovarian cancer between January 01, 2011 and December 31, 2017 in 18 French Comprehensive Cancer Centers (FCCC) were included. The database was locked on January 01, 2020. Propensity scores were performed in population analyses.

**Results** 1831 female patients with FIGO stage III or IV ovarian cancer at diagnosis underwent surgery, including 879 (48%) primary debulking surgery (PDS) and 952 (52%) intermediate and high complexity score. Overall 107 patients were included with a median duration of follow-up of 45 months (24–156). The median surgical complexity score was 7 (4–15). The progression free and overall survival rates of the entire cohort were 28 (22 – 34) and 47 (37–57) months respectively. Sixteen patients experienced a grade IIIB Clavien-Dindo complication. Median high dependency unit stay was 3 days (1–15). Five patients required hospitalization in the intensive care unit. Patients undergoing primary debulking had a clear overall survival benefit compared to patients that had interval debulking surgery (54 months (40–67) vs 35 months (24–46)). Kaplan Meier curves revealed that the difference became evident among patients that survived for at least 50 months. Recurrence free survival was not influenced by this parameter. A progressive decrease in overall survival rates was observed with advancing stage. Complexity of the procedure (intermediate vs high) did not affect survival rates of patients.

**Conclusion** Maximal effort cytoreduction is feasible and is accompanied by acceptable morbidity and mortality rates. Primary debulking should be considered in appropriately selected patients as this considerably increases overall survival rates of patients.